References
- Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006;63:415–24.
- Pollack MH. The pharmacotherapy of panic disorder. J Clin Psychiatry 2005;66(Suppl4):23–7.
- Roy-Byrne P, Stein M, Bystrisky A, Katon W. Pharmacotherapy of panic disorder: proposed guidelines for the family physician. J Am Board Fam Pract 1998;11:282–90.
- Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527–31.
- Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002;7:1115–19.
- Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000;20:105–7.
- Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006;296:1609–18.
- Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383–6.
- Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215–19.
- Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004;161:1575–80.
- Singh AB, Bousman CA, Ng CH, Byron K, Berk M. Psychomotor depressive symptoms may differentially respond to venlafaxine. Int Clin Psychopharmacol 2013;28:121–6.
- Baffa A, Hohoff C, Baune BT, Muller-Tidow C, Tidow N, Freitag C, et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology 2010;62:121–31.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Furukawa TA, Katherine Shear M, Barlow DH, Gorman JM, Woods SW, Money R, et al. Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depress Anxiety 2009;26:922–9.
- Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive–compulsive disorder. Am J Hum Genet 2006;78:815–26.
- Lee YJ, Hohoff C, Domschke K, Sand P, Kuhlenbaumer G, Schirmacher A, et al. Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. Neurosci Lett 2005;377:40–3.
- Kim CH, Kim HS, Cubells JF, Kim KS. A previously undescribed intron and extensive 5' upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem 1999;274:6507–18.
- Buttenschon HN, Kristensen AS, Buch HN, Andersen JH, Bonde JP, Grynderup M, et al. The norepinephrine transporter gene is a candidate gene for panic disorder. J Neural Transm 2011;118:969–76.
- Kim W, Choi YH, Yoon KS, Cho DY, Pae CU, Woo JM. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1413–18.